中国肺癌原创临床研究阶段汇总

2021
07/09

+
分享
评论
e药安全
A-
A+



Lancet Oncol

Lancet Oncol  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Li Zhang (2012)

Lancet Oncol

Lancet Oncol  Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Li Zhang (2013)

J Thorac Oncol

J Thorac Oncol  Final overall survival results from a phase III, randomized,

placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804)  Li Zhang (2015)

Medicine

Medicine  Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung(C-TONG 0807):an open-label,single arm,multicenter phase II study  Li Zhang (2015)

J Thorac Oncol

J Thorac Oncol  First-in-human phase I study of AC0010, a mutant-selective EGFR Inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance  Li Zhang (2018)

Lung Cancer

Lung Cancer Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial   Li Zhang (2018)

J Clin Pharmacol

J Clin Pharmacol Pharmacokinetics of osimertinib in Chinese patients with advanced NSCLC: A phase 1 study  Li Zhang (2018)

Clin Transl Med

Clin Transl Med Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer  Li Zhang (2019)

Lancet Respir Med

Lancet Respir Med  Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial  Li  Zhang (2019)

Lancet Respir Med

Lancet Respir Med Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Li  Zhang (2019)

Transl Lung Cancer Res

Transl Lung Cancer Res  Biosimilar candidate IBI305 pluspaclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer  Li Zhang (2020)

J Thorac Oncol

J Thorac Oncol  Efficacy and safety of Sintilimab plus Pemetrexed and Platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by Innov ENT anti-PD-1-11) Li Zhang (2020)

J Thorac Oncol

J Thorac Oncol Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706)  Li Zhang (2021)

J Thorac Oncol

J Thorac Oncol Decoding the evolutionary response to Ensartinib in ALK-positive non-small-cell lung cancer patients by dynamic circulating tumor DNA sequencing  Li Zhang (2021)

Ann Transl Med

Ann Transl Med Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial Li Zhang (2021)


附鼻咽癌部分

J Clin Oncol

J Clin Oncol Phase III study comparing standard radiotherapy with or without weekly Oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results  Li Zhang (2005)

Cancer Chemother Pharmacol

Cancer Chemother Pharmacol Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy Li Zhang (2008)

Eur J Cancer

Eur J Cancer  Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastase Li Zhang (2011)

Oral Oncol

Oral Oncol A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma  Li Zhang (2012)

Cancer Chemother Pharmacol

Cancer Chemother Pharmacol Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy  Li Zhang (2012)

Lancet

Lancet Gemcitabine plus cisplatin versus fluorouracilplus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial  Li Zhang (2016)

BMC Cancer

BMC Cancer   Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as treatment for metastatic nasopharyngeal carcinoma Li Zhang (2016)

Lancet Oncol

Lancet Oncol Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials  Li Zhang (2018)

Oncologist

Oncologist  A phase I/II open-label study of Nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors  Li Zhang (2019)

Lancet Oncol

Lancet Oncol Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyneal carcinoma (CAPTAIN-1s):a multicentre,randomised,double-blind,phase 3 trial  Li Zhang (2021)

整理者  


本文由作者自行上传,并且作者对本文图文涉及知识产权负全部责任。如有侵权请及时联系(邮箱:nanxingjun@hmkx.cn
关键词:
肺癌,阶段,临床,研究

人点赞

收藏

人收藏

打赏

打赏

我有话说

0条评论

0/500

评论字数超出限制

表情
评论

为你推荐

推荐课程


社群

精彩视频

您的申请提交成功

确定 取消
剩余5
×

打赏金额

认可我就打赏我~

1元 5元 10元 20元 50元 其它

打赏

打赏作者

认可我就打赏我~

×

扫描二维码

立即打赏给Ta吧!

温馨提示:仅支持微信支付!